It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Sana Biotechnology Inc (SANA) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.02, or -0.47%, to $4.28. The Sana Biotechnology Inc has recorded 7,809 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes.
Sana Biotechnology Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $4.30 and fluctuated between $4.5050 as its day high and $4.1500 as its day low. The current market capitalization of Sana Biotechnology Inc is $847.66M. A total of 1.38 million shares were traded on the day, compared to an average of 1.24M shares.
Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, SANA has seen 0 BUY and 6 SELL insider trades, representing the acquisition of 0 and the disposition of 11,781,275 shares. Over the last 12 months, there were 6 BUYs and 14 SELLs from insiders. Insiders purchased 22,665 shares during that period but sold 12,530,275.
In the most recent transaction, Flagship Ventures Fund V Gener sold 200,000 shares of SANA for 6.24 per share on Jun 07. After the transaction, the 10% Owner now owns 1,380,277 company shares. In a previous transaction on Jun 06, Flagship Ventures Fund V Gener sold 203,758 shares at 6.31 per share. SANA shares that 10% Owner owns now total 1,403,037.
Among the insiders who sold shares, Flagship Ventures Fund V Gener disposed of 82,000 shares on May 26 at a per-share price of $6.23. This resulted in the 10% Owner holding 1,425,334 shares of SANA after the transaction. In another insider transaction, Flagship Ventures Fund V Gener sold 115,372 shares at $6.35 per share on May 25. Company shares held by the 10% Owner now total 1,434,664.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for SANA in the last 3 months, the mean price target is $8.80 with high estimates of $13.00 and low estimates of $5.00. In terms of 52-week highs and lows, SANA has a high of $8.01 and a low of $2.74.
As of this writing, SANA has an earnings estimate of -$0.38 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.33 per share and a lower estimate of -$0.42. The company reported an EPS of -$0.59 in the last quarter, which was -37.20% lower than expectations of -$0.43.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. SANA’s latest balance sheet shows that the firm has $746.88M in Cash & Short Term Investments as of fiscal 2021. There were $110.94M in debt and $99.23M in liabilities at the time. Its Book Value Per Share was $1.86, while its Total Shareholder’s Equity was $728.50M.
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for SANA is Buy with a score of 4.00.